Brief: Antengene Announces New Drug Application Approval For Xpovio®
17/07/2023 02:39
July 17 (Reuters) - Antengene Corporation Ltd 6996.HK :
* DEPARTMENT OF HEALTH, GOVERNMENT OF HONG KONG SPECIAL
ADMINISTRATIVE REGION APPROVED CO'S NEW DRUG APPLICATION FOR
XPOVIO®
Source text for Eikon: ID:nHKS1ZchqQ
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106